SHTP.Y Stock Overview

Develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharmaceutical, biotechnology, and life science industries worldwide. More details

SHTP.Y fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (29.7x) is below the Life Sciences industry average (39.1x)

Earnings are forecast to grow 15.89% per year

Earnings grew by 5.4% over the past year

Risk Analysis

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

SCHOTT Pharma AG & Co. KGaA Competitors

Syneos Health

NasdaqGS:SYNH

US$4.5b

Stevanato Group

NYSE:STVN

US$6.5b

Sotera Health

NasdaqGS:SHC

US$3.8b

Bruker

NasdaqGS:BRKR

US$9.2b

Price History & Performance

Summary of share price highs, lows and changes for SCHOTT Pharma KGaA
Historical stock prices
Current Share Price	€11.99
52 Week High	€12.00
52 Week Low	€11.99
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	SHTP.Y	US Life Sciences	US Market
7D	0%	1.8%	-0.5%
1Y	n/a	0.2%	23.2%

Return vs Industry: Insufficient data to determine how SHTP.Y performed against the US Life Sciences industry.

Return vs Market: Insufficient data to determine how SHTP.Y performed against the US Market.

Price Volatility

Is SHTP.Y's price volatile compared to industry and market?
SHTP.Y volatility
SHTP.Y Average Weekly Movement	n/a
Life Sciences Industry Average Movement	9.3%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.6%
10% least volatile stocks in US Market	3.2%

Stable Share Price: SHTP.Y's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine SHTP.Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1884	4,681	n/a	www.schott-pharma.com

SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharmaceutical, biotechnology, and life science industries worldwide. The company offers prefillable glass or polymer syringes, glass vials, cartridges, and ampoules. Its syringe products include syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; and SCHOTT TOPPAC unique, a polymer container.

SCHOTT Pharma AG & Co. KGaA Fundamentals Summary

How do SCHOTT Pharma KGaA's earnings and revenue compare to its market cap?
SHTP.Y fundamental statistics
Market cap	US$4.84b
Earnings (TTM)	US$162.99m
Revenue (TTM)	US$1.03b

29.7x

P/E Ratio

4.7x

P/S Ratio

Is SHTP.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SHTP.Y income statement (TTM)
Revenue	€948.56m
Cost of Revenue	€624.35m
Gross Profit	€324.20m
Other Expenses	€173.79m
Earnings	€150.41m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Dec 12, 2024

Earnings per share (EPS)	1.00
Gross Margin	34.18%
Net Profit Margin	15.86%
Debt/Equity Ratio	24.5%

How did SHTP.Y perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

15%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/11/03 09:40
End of Day Share Price	2024/08/06 00:00
Earnings	2024/06/30
Annual Earnings	2023/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SCHOTT Pharma AG & Co. KGaA is covered by 11 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Gaurav Jain	Barclays
Victoria Lambert	Berenberg
Hugo Solvet	BNP Paribas Exane

SCHOTT Pharma KGaA OTCPK:SHTP.Y Stock Report